Health In Tech Inc., an AI-enabled InsurTech platform announced that its Board of Directors has appointed Zain Hasan as Chief Growth Officer. The appointment reflects the company’s focus on accelerating revenue growth and expanding distribution as it enters its next phase of scale.
Health Technology Insights: Nemluvio Shows Rapid Itch Relief and Sleep Benefits
Zain Hasan joined Health In Tech in September 2025 and has already played a central role in strengthening go-to-market execution, broadening distribution channels, and supporting enterprise growth initiatives. In his new position, he will oversee the company’s overall growth strategy with responsibility for revenue performance across sales, distribution, partnerships, and revenue operations.
Tim Johnson, Chief Executive Officer of Health In Tech, said the company is moving into a period of strong growth that requires focused and disciplined execution across sales and marketing. He noted that Health In Tech’s AI-powered platform is free to use, supports more than one hundred customized healthcare plan designs, and includes AI-driven underwriting that allows brokers to generate bindable stop loss healthcare plan quotes within minutes for employers. Johnson added that since joining the company, Hasan has brought a strong entrepreneurial approach, analytical discipline, and consistent operating rhythm to growth efforts, reinforcing the company’s ability to launch new programs and deepen relationships with broker agencies, third-party administrators, and carriers.
Health Technology Insights: Form Health Offers Clear, Predictable GLP-1 Coverage for Employers
Hasan brings more than fifteen years of experience in the employee benefits and insurance sector. He is a five-time founder and former chief executive officer who has successfully built and exited multiple businesses. His background includes scaling revenue, leading organic and acquisition-driven growth strategies, executing strategic transactions, and building high-performing teams. Health In Tech said his experience aligns closely with the company’s long-term growth objectives and its commitment to creating sustainable value for shareholders.
Health Technology Insights: FDA Approves Exdensur (Depemokimab) for Severe Asthma
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
